

[TROUBLE VIEWING?](#) Click Here to view the Promo card on the web

[SIGN-UP NOW! SIGN-UP NOW!](#) Click to become a Member for Free!



C. diff. Spores and More
Tuesday at 10 AM Pacific
December 05th 2017:Encore: The Latest Developments in C. diff Research and Treatment.

Join us with our guest, Dr Mary Beth Dorr, PhD, Clinical Director, Clinical Research, Infectious Diseases, Merck & Co., Inc. as Mary Beth provides us with an overview of a C. diff. infection, the challenges of recurrence, latest clinical research overview, current treatment landscape, and pending new C. diff infection treatment guidelines from the Infectious Diseases Society of America (IDSA) that are anticipated to come out this fall.

- [SHARE](#)
- [DOWNLOAD PDF](#)
- [GET CODE](#)

Tune in
Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel

- [LISTEN LIVE](#)
- [EPISODE ON DEMAND](#)
- [VIEW HOST PAGE](#)

Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guest



Dr Mary Beth Dorr, PhD, Clinical Director Merck & Co., Inc.
Dr. Mary Beth Dorr is the product development lead for ZINPLAVA (bezlotoxumab), a human monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. She has an undergraduate pharmacy degree from the University of the Sciences' Philadelphia College of Pharmacy and completed a clinical pharmacy residency at the Veteran's Administration Hospital in Philadelphia, completed her PhD in pharmaceuticals with an emphasis on pharmacokinetics and drug metabolism at the University of North Carolina in Chapel Hill. She joined the pharmaceutical industry in 1988, and has devoted her career to the design and implementation of Phase 1 to 4 clinical trials, primarily for anti-in

[Read more](#)

Share This Episode

- [Share On Facebook](#)
- [Share On Twitter](#)
- [Share On LinkedIn](#)

Connect with VoiceAmerica

Download our mobile apps

